Ignite Creation Date:
2025-12-25 @ 1:40 AM
Ignite Modification Date:
2025-12-27 @ 11:13 PM
Study NCT ID:
NCT06770894
Status:
COMPLETED
Last Update Posted:
2025-01-13
First Post:
2025-01-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
DPP4-Inhibitors and Bone Metabolism in Diabetes
Sponsor:
Azienda Policlinico Umberto I
Organization:
Study Overview
Official Title:
A Randomized, Double Blind Placebo Controlled Clinical Trial to Assess the Efficacy and Safety of Sitagliptin on Bone Measures in Women Affected by Type 2 Diabetes. a Gender-oriented Approach to Address a Gender-specific Frailty: the SLowDOWN (SitagLiptin in Diabetes for Osteoporosis in WomeN) Study.
Status:
COMPLETED
Status Verified Date:
2025-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SlowDOWN
Brief Summary:
Background Bone frailty and fractures are common conditions in patients with type 2 diabetes (T2D) and represent a major cause of morbidity and hospitalization in this population. In women, the postmenopausal period is well known to dramatically impact bone mineralization and metabolism, leading to a higher risk of bone fractures. Additionally, hyperglycemia, oxidative stress, and advanced glycation end-products accumulation, as occur in diabetes, negatively impact bone quality. Thus, the coexistence of T2D in postmenopausal women represents a detrimental condition highly increasing the risk of bone fractures and hospitalization.
Dipeptidyl peptidase 4 inhibitors (DPP4-Is) are a promising class of antidiabetic agents with protective effects on bone in experimental conditions. In vivo, higher DPP4 activity correlates with lower bone mineral density (BMD) in women, and DPP4-Is treatment was associated with favorable bone outcomes in the only meta-analysis available on subjects with T2D. However, whether chronic DPP4-I treatment is capable of improving bone outcomes in women affected by T2D has not been explored yet in the context of a specifically designed clinical trial.
Objectives This study is a superiority, double-blinded, randomized, placebo-controlled clinical trial aiming to investigate the safety and efficacy of 52-week sitagliptin 100 mg therapy in improving bone outcomes in women affected by T2D.
Methods For this purpose, the investigators aim to recruit 132 female patients aged ≥18 years with a diagnosis of T2D, BMI between 20-40 kg/m², body weight ≤120 kg, and HbA1c between 6.5 and 7.5%, undergoing treatment with metformin in monotherapy at a stable dose for ≥12 weeks prior to recruitment. The enrolment setting is the Diabetes Outpatients' Clinics, Policlinico Umberto I, Sapienza University of Rome. Screening will be performed among all patients referred to these clinics for diabetes care. Both recruitment and intervention are anticipated to take place over a 36-month period.
Primary outcome measures are: (1) changes in bone mineral density (BMD), estimated by dual-energy x-ray absorptiometry (DXA) for the lumbar spine and femoral neck, and (2) changes in markers of bone formation/resorption from baseline to the end of treatment (week 52). Secondary endpoints are: (I) evaluation of the association between circulating DPP4 activity and serum markers of bone metabolism at baseline and after 24- and 52-week sitagliptin treatment; (II) determination of whether circulating DPP4 activity is associated with impaired vitamin D availability; and (III) investigation of the relationship between DPP4 activity and systemic markers of inflammation throughout the study.
Expected Results Both T2D and osteoporosis are widespread conditions with a strong impact on life expectancy, quality of life, and healthcare costs. It has been estimated that a quarter of all women will suffer from osteoporosis after menopause, with a 30-40% risk of osteoporotic fractures in their lifetime-much higher than the overall risk of breast, uterine, and ovarian cancer. In Italy, osteoporosis accounts for 500 million Euros in hospitalization costs and is associated with high rates of disability with profound social and psychological impacts.
On the other hand, DPP4-Is represent a widespread treatment for T2D, capable of providing adequate glycemic control with a very low risk of hypoglycemia and serious adverse events. Therefore, this study will provide novel and original evidence on the effects of DPP4-Is on bone health in the context of a specifically designed randomized clinical trial. It will address specific frailties in women, such as osteoporosis and fractures, the risk of which is further increased in the presence of diabetes. The demonstration of favorable effects of chronic DPP4-I treatment on bone metabolism may guide clinicians among the large number of therapeutic options for diabetes care, with immediate implications for a multi-approach diabetes treatment strategy.
Dipeptidyl peptidase 4 inhibitors (DPP4-Is) are a promising class of antidiabetic agents with protective effects on bone in experimental conditions. In vivo, higher DPP4 activity correlates with lower bone mineral density (BMD) in women, and DPP4-Is treatment was associated with favorable bone outcomes in the only meta-analysis available on subjects with T2D. However, whether chronic DPP4-I treatment is capable of improving bone outcomes in women affected by T2D has not been explored yet in the context of a specifically designed clinical trial.
Objectives This study is a superiority, double-blinded, randomized, placebo-controlled clinical trial aiming to investigate the safety and efficacy of 52-week sitagliptin 100 mg therapy in improving bone outcomes in women affected by T2D.
Methods For this purpose, the investigators aim to recruit 132 female patients aged ≥18 years with a diagnosis of T2D, BMI between 20-40 kg/m², body weight ≤120 kg, and HbA1c between 6.5 and 7.5%, undergoing treatment with metformin in monotherapy at a stable dose for ≥12 weeks prior to recruitment. The enrolment setting is the Diabetes Outpatients' Clinics, Policlinico Umberto I, Sapienza University of Rome. Screening will be performed among all patients referred to these clinics for diabetes care. Both recruitment and intervention are anticipated to take place over a 36-month period.
Primary outcome measures are: (1) changes in bone mineral density (BMD), estimated by dual-energy x-ray absorptiometry (DXA) for the lumbar spine and femoral neck, and (2) changes in markers of bone formation/resorption from baseline to the end of treatment (week 52). Secondary endpoints are: (I) evaluation of the association between circulating DPP4 activity and serum markers of bone metabolism at baseline and after 24- and 52-week sitagliptin treatment; (II) determination of whether circulating DPP4 activity is associated with impaired vitamin D availability; and (III) investigation of the relationship between DPP4 activity and systemic markers of inflammation throughout the study.
Expected Results Both T2D and osteoporosis are widespread conditions with a strong impact on life expectancy, quality of life, and healthcare costs. It has been estimated that a quarter of all women will suffer from osteoporosis after menopause, with a 30-40% risk of osteoporotic fractures in their lifetime-much higher than the overall risk of breast, uterine, and ovarian cancer. In Italy, osteoporosis accounts for 500 million Euros in hospitalization costs and is associated with high rates of disability with profound social and psychological impacts.
On the other hand, DPP4-Is represent a widespread treatment for T2D, capable of providing adequate glycemic control with a very low risk of hypoglycemia and serious adverse events. Therefore, this study will provide novel and original evidence on the effects of DPP4-Is on bone health in the context of a specifically designed randomized clinical trial. It will address specific frailties in women, such as osteoporosis and fractures, the risk of which is further increased in the presence of diabetes. The demonstration of favorable effects of chronic DPP4-I treatment on bone metabolism may guide clinicians among the large number of therapeutic options for diabetes care, with immediate implications for a multi-approach diabetes treatment strategy.
Detailed Description:
This study is a superiority, double-blinded, randomized, placebo-controlled clinical trial designed to investigate the safety and efficacy of 52-week sitagliptin 100 mg therapy in improving bone outcomes in women affected by type 2 diabetes.
In particular, the primary objective of this study is:
To test the superiority of sitagliptin 100 mg in addition to metformin versus placebo with metformin in improving bone mineral density from baseline to the end of treatment (week 52), as estimated by DXA on the lumbar spine and femoral neck.
Secondary endpoints are:
Evaluation of the association between circulating DPP4 activity and serum markers of bone metabolism at baseline and after 24- and 52-week sitagliptin supplementation.
Determination of whether circulating DPP4 activity is associated with impaired vitamin D availability and whether chronic DPP4 inhibition induces changes in serum vitamin D levels after treatment.
Examination of the relationship between DPP4 activity and systemic markers of inflammation, which are closely related to impaired glucose metabolism, at baseline and after 24- and 52-week sitagliptin supplementation.
In particular, the primary objective of this study is:
To test the superiority of sitagliptin 100 mg in addition to metformin versus placebo with metformin in improving bone mineral density from baseline to the end of treatment (week 52), as estimated by DXA on the lumbar spine and femoral neck.
Secondary endpoints are:
Evaluation of the association between circulating DPP4 activity and serum markers of bone metabolism at baseline and after 24- and 52-week sitagliptin supplementation.
Determination of whether circulating DPP4 activity is associated with impaired vitamin D availability and whether chronic DPP4 inhibition induces changes in serum vitamin D levels after treatment.
Examination of the relationship between DPP4 activity and systemic markers of inflammation, which are closely related to impaired glucose metabolism, at baseline and after 24- and 52-week sitagliptin supplementation.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 2018-000859-40 | EUDRACT_NUMBER | None | View |